![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Real-World Use of Long-Acting Cabotegravir + Rilpivirine in People with HIV with Detectable Viral Loads at Initiation: Findings from the OPERA® Cohort
|
|
|
Ricky K. Hsu
AHF & NYU Langone Health, New York, NY, USA
2 comments during Q&A that they were concerned that these failures might develop INSTI resistance and lose the class. "Limit use to those at severe risk for advanced HIV or mortality".
![1013231](../images/101123/101123-5/1013231.gif)
![1013232](../images/101123/101123-5/1013232.gif)
![1013233](../images/101123/101123-5/1013233.gif)
![1013234](../images/101123/101123-5/1013234.gif)
![1013235](../images/101123/101123-5/1013235.gif)
![1013236](../images/101123/101123-5/1013236.gif)
![1013237](../images/101123/101123-5/1013237.gif)
![1013238](../images/101123/101123-5/1013238.gif)
![1013239](../images/101123/101123-5/1013239.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|